Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research

  • STATUS
    Recruiting
  • participants needed
    9999
  • sponsor
    National Cancer Institute (NCI)
Updated on 7 November 2020
immunohistochemistry

Summary

RATIONALE: Studying samples of tumor tissue or blood from patients with cancer in the laboratory may help doctors learn more about cancer and the development of multidrug resistance in patients. PURPOSE: This laboratory study is looking at multidrug resistance proteins in patients enrolled in clinical trials outside of the National Cancer Institute Center for Cancer Research.

Description

OBJECTIVES: - Determine expression of MDR-1 gene/P-glycoprotein and related drug resistance proteins in tumor tissue samples from patients enrolled in clinical trials outside of the National Cancer Institute Center for Cancer Research. OUTLINE: Tumor tissue or blood samples that have been previously collected from patients are analyzed for P-glycoprotein and other multidrug transporters (e.g., MRP-1 and ABCG2) by immunohistochemistry, microarray analysis, and reverse transcriptase-polymerase chain reaction. The identity of individual patients remains confidential. No results of sample analyses are provided to patients or family members. PROJECTED ACCRUAL: An unlimited number of patient samples will be accrued for this study.

Details
Condition Brain and Central Nervous System Tumors, Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Treatment flow cytometry, immunohistochemistry staining method, Gene Expression Analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction
Clinical Study IdentifierNCT00898001
SponsorNational Cancer Institute (NCI)
Last Modified on7 November 2020

Eligibility

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note